A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease
- PMID: 32571083
- DOI: 10.1177/1060028020935105
A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease
Abstract
Objective: To evaluate glucagon-like peptide 1 receptor agonists (GLP-1 RAs), dipeptidyl-peptidase IV (DPP-4) inhibitors, and sodium-glucose cotransporter 2 (SGLT) inhibitors to treat nondiabetic and type 2 diabetes mellitus (T2DM) nonalcoholic fatty liver disease (NAFLD) as it relates to improvement in hepatosteatosis (HS) or steatohepatitis (SH).
Data sources: MEDLINE and CINAHL were searched from inception through May 1, 2020. Search terms included nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, fatty liver, dipeptidyl-peptidase IV inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose transporter 2 inhibitors.
Study selection and data extraction: Full-text observational and randomized controlled studies in English were included. Patients diagnosed with NAFLD, treated with GLP-1 RAs, DPP-4 inhibitors, and SGLT2 inhibitors, with measures to evaluate HS or SH were evaluated.
Data synthesis: Eight GLP-1 RA trials were reviewed; 7 GLP-1 RA trials showed improvement in HS. Two studies demonstrated improvement in liver histology in patients with SH. Seven SGLT2 inhibitor studies were reviewed; 6 studies demonstrated improvements in NAFLD. Five studies showed improvements in HS, whereas 1 displayed improvement in liver histology in NASH. Six studies that included DPP-4 inhibitors were evaluated, and only 2 demonstrated improvement in NASH.
Relevance to patient care and clinical practice: Based on evidence reviewed, GLP-1 RAs and SGLT2 inhibitors decreased HS and SH in NAFLD patients, whereas DPP-4 inhibitor therapy was not effective for patients with HS.
Conclusions: Based on study data utilizing imaging studies and biopsy results, GLP-1 RAs or SGLT2 inhibitors can benefit NAFLD T2DM patients. Clinical trials with larger patient populations may augment these results.
Keywords: DPP-4 inhibitor; GLP-1 receptor agonist; NAFL; NAFLD; NASH; SGLT-2 inhibitor; diabetes; evidence-based medicine; fatty liver.
Similar articles
-
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!Metabolism. 2019 Dec;101:154001. doi: 10.1016/j.metabol.2019.154001. Epub 2019 Oct 28. Metabolism. 2019. PMID: 31672448 Review.
-
Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.Diabetes Care. 2022 Apr 1;45(4):819-829. doi: 10.2337/dc21-1953. Diabetes Care. 2022. PMID: 35104330
-
Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.Clin Res Hepatol Gastroenterol. 2022 Aug-Sep;46(7):101970. doi: 10.1016/j.clinre.2022.101970. Epub 2022 Jun 1. Clin Res Hepatol Gastroenterol. 2022. PMID: 35659603
-
Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.Curr Vasc Pharmacol. 2020;18(2):172-181. doi: 10.2174/1570161117666190405164313. Curr Vasc Pharmacol. 2020. PMID: 30961499 Review.
-
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.Diabetes Metab. 2020 Nov;46(6):427-441. doi: 10.1016/j.diabet.2019.12.007. Epub 2020 Jan 7. Diabetes Metab. 2020. PMID: 31923578
Cited by
-
Will the COVID-19 Pandemic Finally Fuel Drug Repurposing Efforts?Am J Med Qual. 2021 Mar-Apr 01;36(2):122-124. doi: 10.1097/01.JMQ.0000735440.58551.5b. Am J Med Qual. 2021. PMID: 33830096 Free PMC article. No abstract available.
-
Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective.Diabetes Metab J. 2024 May;48(3):327-339. doi: 10.4093/dmj.2023.0350. Epub 2024 Feb 2. Diabetes Metab J. 2024. PMID: 38310873 Free PMC article. Review.
-
Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.World J Gastroenterol. 2022 Jul 14;28(26):3243-3257. doi: 10.3748/wjg.v28.i26.3243. World J Gastroenterol. 2022. PMID: 36051336 Free PMC article.
-
Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.PLoS One. 2023 Nov 22;18(11):e0294423. doi: 10.1371/journal.pone.0294423. eCollection 2023. PLoS One. 2023. PMID: 37992029 Free PMC article.
-
Anti-inflammatory effects of GLP-1 in patients with COVID-19.Expert Rev Anti Infect Ther. 2022 Mar;20(3):373-381. doi: 10.1080/14787210.2021.1964955. Epub 2021 Aug 12. Expert Rev Anti Infect Ther. 2022. PMID: 34348067 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous